In summary, our results demonstrated that sulindac prevents EMT progression and ameliorates PF by reversing IFN-γ-induced STAT3-related miR-21 expression, which highlightes the mechanism of the sulindac application and provides new targets for PF therapy. This evidence concerns the gene IFNG and pemphigus foliaceus.